RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
RHYTHM PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Read chart description and values below for full signed amounts, including zero items.Maturities of short-term investments → investing reconciliation: $156,750,000.00investing reconciliation → Net cash from investing activities: $71,065,000.00investing reconciliation → Purchases of short-term investments: $85,685,000.00Proceeds from the exercise of stock options → financing reconciliation: $13,094,000.00Proceeds from issuance of common stock from ESPP → financing reconciliation: $1,251,000.00financing reconciliation → Repayment of deferred royalty obligation: $11,195,000.00financing reconciliation → Tax withholding on vesting of restricted stock: $9,715,000.00Net cash used in operating activities → operating reconciliation: $53,337,000.00Stock-based compensation expense → operating reconciliation: $49,155,000.00Accounts payable, accrued expenses and other liabilities → operating reconciliation: $10,838,000.00Non-cash interest expense → operating reconciliation: $9,116,000.00Prepaid expenses and other current assets → operating reconciliation: $2,317,000.00Other non-cash items → operating reconciliation: $665,000.00Change in fair value of embedded derivative liability → operating reconciliation: $560,000.00Depreciation and amortization → operating reconciliation: $503,000.00Other long-term assets, net → operating reconciliation: $435,000.00Foreign currency (gain) loss → operating reconciliation: $337,000.00Non-cash rent expense → operating reconciliation: $232,000.00operating reconciliation → Net loss: $104,937,000.00operating reconciliation → Accounts receivable: $14,326,000.00operating reconciliation → Inventory: $5,428,000.00operating reconciliation → Non-cash accretion & amortization of short-term investments: $2,610,000.00operating reconciliation → Deferred revenue: $194,000.00Net cash used in financing activities → financing reconciliation: $6,565,000.00Exchange-rate effect → Cash sources and uses: $231,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $54,823,000.00Net cash from investing activities → Cash sources and uses: $71,065,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $66,217,000.00Cash sources and uses → Net cash used in financing activities: $6,565,000.00Cash sources and uses → Net cash used in operating activities: $53,337,000.00Net loss: -$104,937,000.00Net loss−$104.94 MStock-based compensation expense: $49,155,000.00Stock-based compensation+$49.16 MDepreciation and amortization: $503,000.00Depreciation and amortization+$503.00 KNon-cash interest expense: $9,116,000.00Non-cash interest expense+$9.12 MNon-cash accretion & amortization of short-term investments: -$2,610,000.00Investment accretion & amort.−$2.61 MNon-cash rent expense: $232,000.00Non-cash rent expense+$232.00 KChange in fair value of embedded derivative liability: $560,000.00Derivative liabilities, net+$560.00 KForeign currency (gain) loss: $337,000.00Unrealized FX gain & loss+$337.00 KAccounts receivable: -$14,326,000.00Accounts receivable−$14.33 MInventory: -$5,428,000.00Inventories−$5.43 MPrepaid expenses and other current assets: $2,317,000.00Prepaid & other assets+$2.32 MDeferred revenue: -$194,000.00Unearned revenue−$194.00 KOther long-term assets, net: $435,000.00Other noncurrent assets+$435.00 KAccounts payable, accrued expenses and other liabilities: $10,838,000.00Payables & accrued liabilities+$10.84 MOther non-cash items: $665,000.00Other non-cash items+$665.00 KNet cash used in operating activities: -$53,337,000.00. Cash required to fund net payments.Operating cash−$53.34 Moperating reconciliation: $127,495,000.00Repayment of deferred royalty obligation: -$11,195,000.00Long-term debt repaid−$11.20 MProceeds from the exercise of stock options: $13,094,000.00Stock option exercises+$13.09 MProceeds from issuance of common stock from ESPP: $1,251,000.00Stock plan proceeds+$1.25 MProceeds from ATM equity offering: $0.00Tax withholding on vesting of restricted stock: -$9,715,000.00Stock-award tax withholding−$9.72 MNet cash used in financing activities: -$6,565,000.00. Cash required to fund net payments.Financing cash−$6.57 Mfinancing reconciliation: $20,910,000.00Purchases of short-term investments: -$85,685,000.00Short-term investment purchases−$85.69 MMaturities of short-term investments: $156,750,000.00Short-term investment maturities+$156.75 MNet cash from investing activities: $71,065,000.00Investing cash+$71.07 Minvesting reconciliation: $156,750,000.00Cash sources and uses: $126,119,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $54,823,000.00Beginning cash$54.82 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $66,217,000.00Ending cash$66.22 MExchange-rate effect: $231,000.00FX effect+$231.00 KCASH RECONCILIATIONInvestingflowsFinancingflowsOperatingflowsNet loss −$104.94M + net operating adjustments $51.60M = operating cash −$53.34MFree cash flowNot availableCash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$11.39 MEnding cash − beginning cash
Chart details

RHYTHM PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
54,823,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
negative 53,337,000 US dollars. Net cash used.
Net loss
negative 104,937,000 US dollars
Stock-based compensation expense
49,155,000 US dollars
Depreciation and amortization
503,000 US dollars
Non-cash interest expense
9,116,000 US dollars
Non-cash accretion & amortization of short-term investments
negative 2,610,000 US dollars
Non-cash rent expense
232,000 US dollars
Change in fair value of embedded derivative liability
560,000 US dollars
Foreign currency (gain) loss
337,000 US dollars
Accounts receivable
negative 14,326,000 US dollars
Inventory
negative 5,428,000 US dollars
Prepaid expenses and other current assets
2,317,000 US dollars
Deferred revenue
negative 194,000 US dollars
Other long-term assets, net
435,000 US dollars
Accounts payable, accrued expenses and other liabilities
10,838,000 US dollars
Other non-cash items
665,000 US dollars
Investing activities
71,065,000 US dollars. Net cash provided.
Purchases of short-term investments
negative 85,685,000 US dollars
Maturities of short-term investments
156,750,000 US dollars
Financing activities
negative 6,565,000 US dollars. Net cash used.
Repayment of deferred royalty obligation
negative 11,195,000 US dollars
Proceeds from the exercise of stock options
13,094,000 US dollars
Proceeds from issuance of common stock from ESPP
1,251,000 US dollars
Proceeds from ATM equity offering
0 US dollars
Tax withholding on vesting of restricted stock
negative 9,715,000 US dollars
Operating adjustment reconciliation
127,495,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
20,910,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
156,750,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
231,000 US dollars
Ending cash on Jun 30, 2026
66,217,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
126,119,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
11,394,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$104.94M + net operating adjustments $51.60M = operating cash −$53.34M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!